Original Paper

LPA and PLG Sequence Variation and Kringle IV-2 Copy Number in Two Populations
Dana C. Crawford^a, Ze Peng^b, Jan-Fang Cheng^b, Dario Boffelli^b, Magdalena Ahearn^c, Dan Nguyen^c, Tristan Shaffer^c, Qian Yi^c, Robert J. Livingston^c, Mark J. Rieder^c, Deborah A. Nickerson<sup>c

a</sup>Department of Molecular Physiology and Biophysics, Center for Human Genetics Research, Vanderbilt University, Nashville, Tenn.;
^bGenomics Division and Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, Calif.; and
^cDepartment of Genome Sciences, University of Washington, Seattle, Wash., USA

Address of Corresponding Author

Hum Hered 2008;66:199-209 (DOI: 10.1159/000143403)

  Key Words

• African-American
• Apo(a)
• Kringle
• Lp(a)
• Plasminogen
• Sequencing
• Linkage disequilibrium

  Abstract

Background/Aims: Lp(a) levels have long been recognized as a potential risk factor for coronary heart disease that is almost completely under genetic control. Much of the genetics impacting Lp(a) levels has been attributed to the highly polymorphic LPA kringle IV-2 copy number variant, and most of the variance in Lp(a) levels in populations of European-descent is inversely correlated with kringle IV copy number. However, less of the variance is explained in African-descent populations for the same structural variation. African-descent populations have, on average, higher levels of Lp(a), suggesting other genetic factors contribute to Lp(a) level variability across populations. Methods: To identify potential cis-acting factors, we re-sequenced the gene LPA for single nucleotide polymorphism (SNP) discovery in 23 European-Americans and 24 African-Americans. We also re- sequenced the neighboring gene plasminogen (PLG) and genotyped the kringle IV copy number variant in the same reference samples. Results: These data are the most comprehensive description of sequence variation in LPA and its relationship with the kringle IV copy number variant. With these data, we demonstrate that only a fraction of LPA sequence diversity has been previously documented. Also, we identify several high frequency SNPs present in the African-American sample but absent in the European-American sample. Finally, we show that SNPs within PLG are not in linkage disequilibrium with SNPs in LPA, and we show that kringle IV copy number variation is not in linkage disequilibrium with either LPA or PLG SNPs. Conclusions: Together, these data suggest that LPA SNPs could independently contribute to Lp(a) levels in the general population.

Copyright © 2008 S. Karger AG, Basel

  References

1.

Scanu AM: Lp(a) lipoprotein - coping with heterogeneity. N Engl J Med 2003;349:2089-2090.

2.

Koschinsky ML, Cote GP, Gabel B, van der Hoek YY: Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. J Biol Chem 1993;268:19819-19825.

3.

Kraft HG, Menzel HJ, Hoppichler F, Vogel W, Utermann G: Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest 1989;83:137-142.

4.

White AL, Lanford RE: Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes. J Biol Chem 1994;269:28716-28723.

5.

Rotimi CN, Cooper RS, Marcovina SM, McGee D, Owoaje E, Ladipo M: Serum distribution of lipoprotein(a) in African Americans and Nigerians: Potential evidence for a genotype-environmental effect. Genet Epidemiol 1997;14:157-168.

6.

Marcovina SM, Gaur VP, Albers JJ: Biological variability of cholesterol, triglyceride, low- and high-density lipoprotein cholesterol, lipoprotein(a), and apolipoproteins A- I and B. Clin Chem 1994;40:574-578.

7.

Cobbaert C, Arentsen JC, Mulder P, Hoogerrugge N, Lindemans J: Significance of various parameters derived from biological variability of lipoprotein(a), homocysteine, cysteine, and total antioxidant status. Clin Chem 1997;43:1958-1964.

8.

Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S: Report of the National Heart, Lung, and Blood Institute workshop on lipoprotein(a) and cardiovascular disease: recent advances and future directions. Clin Chem 2003;49:1785-1796.

9.

McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM: cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:132-137.

10.

Boffelli D, Cheng J-F, Rubin EM: Convergent evolution in primates and an insectivore. Genomics 2004;83:19-23.

11.

Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH: Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992;90:52-60.

12.

Boomsma DI, de Knijff P, Labeur C, Martin NG, Havekes LM, Princen HMG: The effect of apolipoprotein(a)-, apolipoprotein E-, and apolipoprotein A4-polymorphisms on quantitative lipoprotein(a) concentrations. Twin Res 2000;3:152-158.

13.

Kraft HG, Lingenhel A, Pang RW, Delport R, Trommsdorff M, Vermaak H, Janus ED, Utermann G: Frequency distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a) levels in Caucasian, Asian, and African populations: The distribution of null alleles is non-random. Eur J Hum Genet 1996;4:74-87.

14.

Schmidt K, Kraft HG, Parson W, Utermann G: Genetics of the Lp(a)/apo(a) system in an autochthonous Black African population from the Gabon. Eur J Hum Genet 2006;14:190-201.

15.

Ali S, Bunker CH, Aston CE, Ukoli FA, Kamboh MI: Apolipoprotein A kringle 4 polymorphism and serum lipoprotein(a) concentrations in African blacks. Hum Biol 1998;70:477-490.

16.

Marcovina SM, Albers JJ, Jacobs DR Jr, Perkins LL, Lewis CE, Howard BV, Savage P: Lipoprotein[a] concentrations and apolipoprotein[a] phenotypes in Caucasians and African Americans. The CARDIA study. Arterioscler Thromb 1993;13:1037-1045.

17.

Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lackner C, Csaszar A, Boerwinkle E, Utermann G: Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet 1991;86:607-614.

18.

Danesh J, Collins R, Peto R: Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102:1082-1085.

19.

Danik JS, Rifai N, Buring JE, Ridker PM: Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 2006;296:1363-1370.

20.

Guerra R, Yu Z, Marcovina S, Peshock R, Cohen JC, Hobbs HH: Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the dallas heart study. Circulation 2005;111:1471-1479.

21.

Moliterno DJ, Jokinen EV, Miserez AR, Lange RA, Willard JE, Boerwinkle E, Hillis LD, Hobbs HH: No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. Arterioscler Thromb Vasc Biol 1995;15:850-855.

22.

Paultre F, Pearson TA, Weil HFC, Tuck CH, Myerson M, Rubin J, Francis CK, Marx HF, Philbin EF, Reed RG, Berglund L: High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white Men. Arterioscler Thromb Vasc Biol 2000;20:2619-2624.

23.

Marcovina SM, Albers JJ, Wijsman E, Zhang ZH, Chapman NH, Kennedy H: Differences in Lp(a) concentrations and apo(a) polymorphs between black and white Americans. J Lipid Res 1996;37:2569-2585.

24.

Boerwinkle E, Menzel HJ, Kraft HG, Utermann G: Genetics of the quantitative Lp(a) lipoprotein trait. III. Contribution of Lp(a) glycoprotein phenotypes to normal lipid variation. Hum Genet 1989;82:73-78.

25.

Scholz M, Kraft HG, Lingenhel A, Delport R, Vorster EH, Bickeboller H, Utermann G: Genetic control of lipoprotein(a) concentrations is different in Africans and Caucasians. Eur J Hum Genet 1999;7:169-178.

26.

Mooser V, Scheer D, Marcovina SM, Wang J, Guerra R, Cohen J, Hobbs HH: The Apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African Americans. Am J Hum Genet 1997;61:402-417.

27.

Barkley RA, Brown AC, Hanis CL, Kardia SL, Turner ST, Boerwinkle E: Lack of genetic linkage evidence for a trans-acting factor having a large effect on plasma lipoprotein[a] levels in African Americans. J Lipid Res 2003;44:1301-1305.

28.

Dausset J, Cann H, Cohen D, Lathrop M, Lalouel JM, White R: Centre d'etude du polymorphisme humain (CEPH): collaborative genetic mapping of the human genome. Genomics 1990;6:575-577.

29.

Meucci MA, Marsh S, Watters JW, McLeod HL: CEPH individuals are representative of the European American population: implications for pharmacogenetics. Pharmacogenomics 2005;6:59-63.

30.

Reiner AP, Carlson CS, Rieder MJ, Siscovick DS, Liu K, Chandler WL, Green D, Schwartz SM, Nickerson DA: Coagulation factor VII gene haplotypes, obesity-related traits, and cardiovascular risk in young women. J Thromb Haemost 2007;5:42-49.

31.

Reiner AP, Carty CL, Carlson CS, Wan JY, Rieder MJ, Smith JD, Rice K, Fornage M, Jaquish CE, Williams OD, Tracy RP, Lewis CE, Siscovick DS, Boerwinkle E, Nickerson DA: Association between patterns of nucleotide variation across the three fibrinogen genes and plasma fibrinogen levels: the Coronary Artery Risk Development in Young Adults (CARDIA) study. J Thromb Haemost 2006;4:1279-1287.

32.

Carlson CS, Aldred SF, Lee PK, Tracy RP, Schwartz SM, Rieder M, Liu K, Williams OD, Iribarren C, Lewis EC, Fornage M, Boerwinkle E, Gross M, Jaquish C, Nickerson DA, Myers RM, Siscovick DS, Reiner AP: Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005;77:64-77.

33.

Crawford DC, Sanders CL, Qin X, Smith JD, Shephard C, Wong M, Witrak L, Rieder MJ, Nickerson DA: Genetic variation is associated with C-reactive protein levels in the Third National Health and Nutrition Examination Survey. Circulation 12-5-2006;114:2458-2465.

34.

Tajima F: Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics 1989;123:585.

35.

Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH: Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 1991;87:2077-2086.

36.

Gaw A, Boerwinkle E, Cohen JC, Hobbs HH: Comparative analysis of the Apo(a) gene, apo(a) glycoprotein, and plasma concentration of Lp(a) in three ethnic groups. J Clin Invest 1994;93:2526-2534.

37.

Puckey LH, Lawn RM, Knight BL: Polymorphisms in the apolipoprotein(a) gene and their relationship to allele size and plasma lipoprotein(a) concentration. Hum Mol Genet 1997;6:1099-1107.

38.

Bhangale TR, Rieder MJ, Livingston R, Nickerson DA: Comprehensive identification and characterization of diallelic insertion-deletion polymorphisms in 330 human candidate genes. Hum Mol Genet 2005;14:59.

39.

Crawford DC, Akey DT, Nickerson DA: The patterns of natural variation in human genes. Annu Rev Genomics Hum Genet 2005;6:287-312.

40.

Biswas S, Akey JM: Genomic insights into positive selection. Trends Genet 2006;22:437-446.

41.

Carlson CS, Eberle MA, Rieder MJ, Smith JD, Kruglyak L: Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans. Nat Genet 2003;33:518.

42.

Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 1999;22:231.

43.

Reich DE, Cargill M, Bolk S, Ireland J, Sabeti PC: Linkage disequilibrium in the human genome. Nature 2001;411:199.

44.

Yang Z, Boffelli D, Boonmark N, Schwartz K, Lawn R: Apolipoprotein(a) gene enhancer resides within a LINE element. J Biol Chem 1998;273:891-897.

45.

Huby T, Afzal V, Doucet C, Lawn RM, Gong EL, Chapman MJ, Thillet J, Rubin EM: Regulation of the expression of the apolipoprotein(a) gene: Evidence for a regulatory role of the 5' distal apolipoprotein(a) transcription control region enhancer in yeast artificial chromosome transgenic mice. Arterioscler Thromb Vasc Biol 2003;23:1633-1639.

46.

Wade DP, Puckey LH, Knight BL, Acquati F, Mihalich A, Taramelli R: Characterization of multiple enhancer regions upstream of the apolipoprotein(a) gene. J Biol Chem 1997;272:30387-30399.

47.

Kraft HG, Kochl S, Menzel HJ, Sandholzer C, Utermann G: The apolipoprotein(a) gene: A transcribed hypervariable locus controlling plasma lipoprotein(a) concentration. Hum Genet 1992;90:220-230.

48.

Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C: Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987;80:458-465.

49.

Gavish D, Azrolan N, Breslow JL: Plasma Lp(a) concentration is inversely correlated with the ratio of kringle IV/kringle V encoding domains in the apo(a) gene. J Clin Invest 1989;84:2021-2027.

50.

Chretien JP, Coresh J, Berthier-Schaad Y, Kao WH, Fink NE, Klag MJ, Marcovina SM, Giaculli F, Smith MW: Three single-nucleotide polymorphisms in LPA account for most of the increase in lipoprotein(a) level elevation in African Americans compared with European Americans. J Med Genet 2006;43:917-923.

51.

Suzuki K, Kuriyama M, Saito T, Ichinose A: Plasma lipoprotein(a) levels and expression of the apolipoprotein(a) gene are dependent on the nucleotide polymorphisms in its 5'-flanking region. J Clin Invest 1997;99:1361-1366.

52.

Mancini FP, Mooser V, Guerra R, Hobbs HH: Sequence microheterogeneity in apolipoprotein(a) gene repeats and the relationship to plasma Lp(a) levels. Hum Mol Genet 1995;4:1535-1542.

53.

Ogorelkova M, Kraft HG, Ehnholm C, Utermann G: Single nucleotide polymorphisms in exons of the apo(a) kringles IV types 6 to 10 domain affect Lp(a) plasma concentrations and have different patterns in Africans and Caucasians. Hum Mol Genet 2001;10:815-824.

54.

Kraft HG, Windegger M, Menzel HJ, Utermann G: Significant impact of the +93 C/T polymorphism in the apolipoprotein(a) gene on Lp(a) concentrations in Africans but not in Caucasians: confounding effect of linkage disequilibrium. Hum Mol Genet 1998;7:257-264.

55.

Ichinose A, Kuriyama M: Detection of polymorphisms in the 5'-flanking region of the gene for apolipoprotein(a). Biochem Biophys Res Comm 1995;209:372-378.

56.

Luke MM, Kane JP, Liu DM, Rowland CM, Shiffman D, Cassano J, Catanese JJ, Pullinger CR, Leong DU, Arellano AR, Tong CH, Movsesyan I, Naya-Vigne J, Noordhof C, Feric NT, Malloy MJ, Topol EJ, Koschinsky ML, Devlin JJ, Ellis SG: A Polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol 2007;27:2030-2036.

57.

Simo JM, Joven J, Vilella E, Ribas M, Figuera L, Virgos C, Sundaram IM, Hoover-Plow J: Polymorphisms in human apolipoprotein(a) kringle IV-10 and coronary artery disease: Relationship to allele size, plasma lipoprotein(a) concentration, and lysine binding activity. J Mol Med 2001;79:294-299.

58.

Wade DP, Clarke JG, Lindahl GE, Liu AC, Zysow BR, Meer K, Schwartz K, Lawn RM: 5' control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family. Proc Natl Acad Sci USA 1993;90:1369-1373.

59.

Wu JH, Lee IN: Studies of apolipoprotein (a) promoter from subjects with different plasma lipoprotein (a) concentrations. Clin Biochem 2003;36:241-246.

60.

Zysow BR, Lindahl GE, Wade DP, Knight BL, Lawn RM: C/T polymorphism in the 5' untranslated region of the apolipoprotein(a) gene introduces an upstream ATG and reduces in vitro translation. Arterioscler Thromb Vasc Biol 1995;15:58-64.

61.

Puckey LH, Knight BL: Sequence and functional changes in a putative enhancer region upstream of the apolipoprotein(a) gene. Atherosclerosis 2003;166:119-127.

62.

Rosby O, Alestrom P, Berg K: High-degree sequence conservation in LPA kringle IV-type 2 exons and introns. Clin Genet 1997;52:293-302.

63.

Prins J, Leus FR, Bouma BN, van Rijn HJ: The identification of polymorphisms in the coding region of the apolipoprotein(a) gene. Thromb Haemost 1999;82:1709-1717.

64.

Kraft HG, Haibach C, Lingenhel A, Brunner C, Trommsdorff M, Kronenberg F, Muller HJ, Utermann G: Sequence polymorphism in kringle IV 37 in linkage disequilibrium with the apolipoprotein(a) size polymorphism. Hum Genet 1995;95:275-282.

65.

van der Hoek YY, Wittekoek ME, Beisiegel U, Kastelein JJ, Koschinsky ML: The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms. Hum Mol Genet 1993;2:361-366.

66.

Scanu AM, Pfaffinger D, Lee JC, Hinman J: A single point mutation (Trp72 Arg) in human apo(a) kringle 4-37 associated with a lysine binding defect in Lp(a). Biochim Biophys Acta 1994;1227:41-45.

67.

Prins J, Leus FR, van der Hoek YY, Kastelein JJ, Bouma BN, van Rijn HJ: The identification and significance of a Thr Pro polymorphism in kringle IV type 8 of apolipoprotein(a). Thromb Haemost 1997;77:949- 954.

68.

Ogorelkova M, Gruber A, Utermann G: Molecular basis of congenital lp(a) deficiency: A frequent apo(a) 'null' mutation in Caucasians. Hum Mol Genet 1999;8:2087-2096.

69.

Parson W, Kraft HG, Niederstatter H, Lingenhel AW, Kochl S, Fresser F, Utermann G: A common nonsense mutation in the repetitive Kringle IV-2 domain of human apolipoprotein(a) results in a truncated protein and low plasma Lp(a). Hum Mutat 2004;24:474-480.

70.

Rosby O, Alestrom P, Berg K: Sequence conservation in kringle IV-type 2 repeats of the LPA gene. Atherosclerosis 2000;148:353-364.

71.

Cohen JC, Chiesa G, Hobbs HH: Sequence polymorphisms in the apolipoprotein(a) gene. Evidence for dissociation between apolipoprotein(a) size and plasma lipoprotein(a) levels. J Clin Invest 1993;91:1630-1636.

72.

Perombelon YFN, Soutar AK, Knight BL: Variation in lipoprotein(a) concentration associated with different apolipoprotein(a) alleles. J Clin Invest 1994;93:1481-1492.

73.

Kim JH, Roh KH, Nam SM, Park HY, Jang Y, Kim DK, Song KS: The apolipoprotein(a) size, pentanucleotide repeat, C/T(+93) polymorphisms of apolipoprotein(a) gene, serum lipoprotein(a) concentrations and their relationship in a Korean population. Clin Chim Acta 2001;314:113-123.

74.

Kruglyak L, Nickerson DA: Variation is the spice of life. Nat Genet 2001;27:234.

75.

Crawford DC, Yi Q, Smith JD, Shephard C, Wong M, Witrak L, Livingston RJ, Rieder MJ, Nickerson DA: Allelic spectrum of the natural variation in CRP. Hum Genet 2006;119:496-504.

76.

Glatt CE, DeYoung JA, Delgado S: Screening a large reference sample to identify very low frequency sequence variants: comparisons between two genes. Nat Genet 2001;27:435.

77.

Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H, Shapero MH, Carson AR, Chen W, Cho EK, Dallaire S, Freeman JL, Gonzalez JR, Gratacos M, Huang J, Kalaitzopoulos D, Komura D, MacDonald JR, Marshall CR, Mei R, Montgomery L, Nishimura K, Okamura K, Shen F, Somerville MJ, Tchinda J, Valsesia A, Woodwark C, Yang F, Zhang J, Zerjal T, Zhang J, Armengol L, Conrad DF, Estivill X, Tyler-Smith C, Carter NP, Aburatani H, Lee C, Jones KW, Scherer SW, Hurles ME: Global variation in copy number in the human genome. Nature 2006;444:444-454.

  Author Contacts

Dana C. Crawford, PhD
Department of Molecular Physiology and Biophysics
Center for Human Genetics Research, Vanderbilt University
515B Light Hall, 2215 Garland Avenue, Nashville, TN 37232 (USA)
Tel. +1 615 343 7852, Fax +1 615 343 8619, E-Mail crawford@chgr.mc.vanderbilt.edu

  Article Information

Received: August 20, 2007
Accepted after revision: November 7, 2007
Published online: July 9, 2008
Number of Print Pages : 11
Number of Figures : 2, Number of Tables : 3, Number of References : 77

  Publication Details

Human Heredity (International Journal of Human and Medical Genetics)

Vol. 66, No. 4, Year 2008 (Cover Date: October 2008)

Journal Editor: Devoto M. (Philadelphia, Pa.)
ISSN: 0001-5652 (Print), eISSN: 1423-0062 (Online)

For additional information: http://www.karger.com/HHE

  Drug Dosage / Copyright

Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.